Source:http://linkedlifedata.com/resource/pubmed/id/15376310
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2004-9-22
|
| pubmed:abstractText |
Hepatitis C virus (HCV)-induced cirrhosis is the commonest indication for orthotopic liver transplantation, but HCV recurrence is nearly universal and may worsen patient / graft outcomes. The frequency and severity of HCV recurrence has apparently increased in recent years, raising concern about a possible role for newer immunosuppression regimens in this increase, including potentially tacrolimus. We randomized 79 patients to receive tacrolimus or cyclosporine as primary immunosuppressant posttransplantation. A pathologist blinded to treatment reviewed serial liver biopsies. Month 12 cumulative probabilities of histological hepatitis C recurrence for tacrolimus- and cyclosporine-treated patients were .38 and .54 (P = .19) and failure / death were .25 and .28, respectively (P = .789). Although cyclosporine-treated patients had significantly larger increases in median serum HCV RNA levels (months 1, 6, and 12), no significant differences were observed between the two treatment arms in histologically-diagnosed HCV recurrence / survival rates. In conclusion, choice of calcineurin inhibitors does not impact severity of recurrent HCV.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1527-6465
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1258-62
|
| pubmed:meshHeading |
pubmed-meshheading:15376310-Adult,
pubmed-meshheading:15376310-Biopsy, Needle,
pubmed-meshheading:15376310-Cyclosporine,
pubmed-meshheading:15376310-Female,
pubmed-meshheading:15376310-Hepacivirus,
pubmed-meshheading:15376310-Hepatitis C,
pubmed-meshheading:15376310-Humans,
pubmed-meshheading:15376310-Immunosuppressive Agents,
pubmed-meshheading:15376310-Liver,
pubmed-meshheading:15376310-Liver Cirrhosis,
pubmed-meshheading:15376310-Liver Transplantation,
pubmed-meshheading:15376310-Male,
pubmed-meshheading:15376310-Middle Aged,
pubmed-meshheading:15376310-Prospective Studies,
pubmed-meshheading:15376310-RNA, Viral,
pubmed-meshheading:15376310-Recurrence,
pubmed-meshheading:15376310-Tacrolimus,
pubmed-meshheading:15376310-Treatment Outcome
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
|
| pubmed:affiliation |
Liver Transplant Program, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. martinpx@cshs.org
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|